Your browser doesn't support javascript.
loading
Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer.
Yamashita, Shinichi; Suzukamo, Yoshimi; Kakimoto, Kenichi; Uemura, Motohide; Kishida, Takeshi; Kawai, Koji; Nakamura, Terukazu; Goto, Takayuki; Osawa, Takahiro; Yamada, Shigeyuki; Nishimura, Kazuo; Nonomura, Norio; Nishiyama, Hiroyuki; Shiraishi, Takumi; Ukimura, Osamu; Ogawa, Osamu; Shinohara, Nobuo; Ito, Akihiro; Arai, Yoichi.
Afiliación
  • Yamashita S; Department of, Departments of, Urology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Suzukamo Y; Department of, Physical Medicine and Rehabilitation, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Kakimoto K; Department of Urology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
  • Uemura M; Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Kishida T; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • Kawai K; Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Nakamura T; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
  • Goto T; Department of Urology, Saiseikai Imperial Gift Foundation Inc. Saiseikai Suita Hospital, Suita, Osaka, Japan.
  • Osawa T; Department of Urology, Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, Kyoto, Japan.
  • Yamada S; Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Nishimura K; Department of, Departments of, Urology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Nonomura N; Department of Urology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
  • Nishiyama H; Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Shiraishi T; Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Ukimura O; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
  • Ogawa O; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
  • Shinohara N; Department of Urology, Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, Kyoto, Japan.
  • Ito A; Department of Urology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Arai Y; Department of, Departments of, Urology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Int J Urol ; 28(2): 176-182, 2021 Feb.
Article en En | MEDLINE | ID: mdl-33174259
ABSTRACT

OBJECTIVE:

To validate the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 in Japanese-speaking testicular cancer survivors.

METHODS:

A total of 200 testicular cancer survivors were recruited at eight high-volume institutions in Japan. The participants completed the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and the International Index of Erectile Function 15 questionnaires. A total of 40 participants completed a retest of the questionnaires 2 weeks after the first response. The psychometric properties of the Japanese version including test-retest reliability, internal consistency and concurrent validity were evaluated.

RESULTS:

The mean age at response was 43 years (range 22-74 years), and the mean period after treatment was 77 months (range 0-416 months). The response rate for each item, except sexual function, was high, and the percentage of missing values was less than 3.5%. For test-retest reliability, seven of 12 scales met the criteria (intraclass correlation 0.70-0.86). For internal consistency, four of seven scales met the criteria (Cronbach's alpha 0.62-0.91). For concurrent validity, treatment side effects of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were related to some domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. The sex-related subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were moderately correlated with some International Index of Erectile Function 15 domains.

CONCLUSIONS:

The psychometric properties of the Japanese version are equivalent to the properties of the original European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26. The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 questionnaire is a useful tool to assess the health-related quality of life of testicular cancer patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Testiculares Aspecto: Patient_preference Límite: Child / Child, preschool / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: Int J Urol Asunto de la revista: UROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Testiculares Aspecto: Patient_preference Límite: Child / Child, preschool / Humans / Infant / Male País/Región como asunto: Asia Idioma: En Revista: Int J Urol Asunto de la revista: UROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Japón